Evidence map›Paper›PMID 29130349›Full record

ReviewExpert opinion on biological therapy2018

Regenerating β cells of the pancreas - potential developments in diabetes treatment.

Shengli Dong, Hongju Wu

Abstract readReview
In one paragraph

Review in Expert opinion on biological therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Antidiabetic Effects and Mechanisms of Action of Uncaria gambir Roxb. in Diabetic Sprague-Dawley Rats.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025
    Article
  4. Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024
    Review
  5. Pax4 in Health and Diabetes.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Emergence of microneedles as a potential therapeutics in diabetes mellitus.Environmental science and pollution research international · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Shengli Donga Department of Biochemistry & Molecular Biology , Louisiana State University Health Science Center , New Orleans , LA , USA.
Hongju Wub Department of Medicine , Tulane University Health Science Center , New Orleans , LA , USA.ORCID 0000-0003-0926-8655
Louisiana State University Health Sciences Center New Orleans · USTulane University · US

Funding

Improving Islet Transplantation Outcome With Akt1R01DK081463 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WU, HONGJU · 2009 to 2013
$1.6M
Pax4-induced alpha-to-beta cell conversionR01DK107412 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI WU, HONGJU · 2016 to 2018
$1.0M
NIDDK NIH HHS R01 DK081463NIDDK NIH HHS R01 DK107412
6 · The paper itself

Abstract

introductionThe etiology of diabetes is mainly attributed to insulin deficiency due to the lack of β cells (type 1), or to insulin resistance that eventually results in β cell dysfunction (type 2). Therefore, an ultimate cure for diabetes requires the ability to replace the lost insulin-secreting β cells. Strategies for regenerating β cells are under extensive investigation. AREAS COVERED: Herein, the authors first summarize the mechanisms underlying embryonic β cell development and spontaneous adult β cell regeneration, which forms the basis for developing β cell regeneration strategies. Then the rationale and progress of each β cell regeneration strategy is reviewed. Current β cell regeneration strategies can be classified into two main categories: in vitro β cell regeneration using pluripotent stem cells and in vivo reprogramming of non-β cells into β cells. Each has its own advantages and disadvantages. EXPERT OPINION: Regenerating β cells has shown its potential as a cure for the treatment of insulin-deficient diabetes. Much progress has been made, and β cell regeneration therapy is getting closer to a clinical reality. Nevertheless, more hurdles need to be overcome before any of the strategies suggested can be fully translated from bench to bedside.

Indexed as

Cell- and Tissue-Based TherapyCell DifferentiationCellular ReprogrammingDiabetes MellitusGlucagon-Secreting CellsHuman Embryonic Stem CellsHumansInsulin-Secreting CellsPluripotent Stem CellsRegenerationdiabetesreprogrammingstem cellsβ Cell regeneration

Identifiers

PMID29130349
PMCPMC6135091
OpenAlexW2769109513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.